Cantor Fitzgerald Predicts DRUG FY2025 Earnings

Bright Minds Biosciences Inc. (NASDAQ:DRUG) – Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Bright Minds Biosciences in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan expects that the company will post earnings of ($0.62) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Bright Minds Biosciences’ current full-year earnings is ($2.58) per share.

Bright Minds Biosciences (NASDAQ:DRUG) last issued its earnings results on Monday, December 30th. The company reported ($0.12) earnings per share (EPS) for the quarter.

A number of other equities research analysts have also weighed in on the company. Robert W. Baird assumed coverage on shares of Bright Minds Biosciences in a research note on Monday, November 25th. They set an “outperform” rating and a $75.00 price target on the stock. HC Wainwright initiated coverage on shares of Bright Minds Biosciences in a report on Friday, January 10th. They issued a “buy” rating and a $85.00 target price for the company. Piper Sandler assumed coverage on Bright Minds Biosciences in a research note on Thursday. They set an “overweight” rating and a $93.00 price target on the stock. Finally, Baird R W raised Bright Minds Biosciences to a “strong-buy” rating in a research note on Monday, November 25th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Bright Minds Biosciences has an average rating of “Buy” and a consensus price target of $84.33.

Bright Minds Biosciences Price Performance

Shares of NASDAQ:DRUG opened at $32.28 on Thursday. The company has a 50-day simple moving average of $38.36 and a 200-day simple moving average of $21.08. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.31 and a current ratio of 11.31. The stock has a market capitalization of $143.13 million, a price-to-earnings ratio of -64.56 and a beta of -6.52. Bright Minds Biosciences has a one year low of $0.93 and a one year high of $79.02.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.